Search
Methylprednisolone hemisuccinate
go.drugbank.com/drugs/DB14644ApprovedInvestigationalA water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersBetamethasone phosphate
go.drugbank.com/drugs/DB14669ApprovedVet approved[L11994] Betamethasone provides greater anti-inflammatory activity than [prednisolone] with less sodium and water retention.
Categories: P-glycoprotein inducers, Cytochrome P-450 CYP3A InducersRemdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigationalSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress s...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDordaviprone
go.drugbank.com/drugs/DB14844ApprovedInvestigational[A274391] Dordaviprone has several modes of action, including the activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 InducersAbrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAbrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function. The Janus kinase (JAK)–signal trans...
Synonyms: PF-04965842Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. … [A275455,L56096] By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2C8 InducersDifamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigationalAtopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. This skin disease occurs most frequently in children and can have an...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersInavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalactivity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme InducersXanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigationalSchizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine. Positive symptoms (e.g. hallucinations, delusions) have traditionally been attributed to increased do...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Fezolinetant, an NK3 receptor antagonist, was developed in response to this issue as well as more understanding of the role of NK3R in the hypothalamic-pituitary-gonadal (HPG) axis. … [A259542] Although previous NK3 receptor antagonists exist, such as osanetant and talnetant, only fezolinetant showed tangible effects on the HPC axis, potentially due to its favorable pharmacokinetics
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates